Skip to main content
logo
Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.940
+0.020 (1.04%)
At close: Sep 18, 2026, 4:00 PM EDT
1.950
+0.010 (0.52%)
After-hours: Sep 18, 2026, 7:50 PM EDT

Autolus Therapeutics Revenue

Autolus Therapeutics had revenue of $45.69M in the quarter ending June 30, 2026, with 118.37% growth. This brings the company's revenue in the last twelve months to $117.39M, up 293.55% year-over-year. In the year 2025, Autolus Therapeutics had annual revenue of $75.39M with 652.77% growth.

Revenue (ttm)
$117.39M
Revenue Growth
+293.55%
P/S Ratio
4.40
Revenue / Employee
$155,690
Employees
754
Market Cap
516.36M

Revenue Chart

Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202575.39M65.37M652.77%
Dec 31, 202410.01M8.32M489.80%
Dec 31, 20231.70M-4.68M-73.38%
Dec 31, 20226.38M4.87M323.23%
Dec 31, 20211.51M1.27M522.73%
Dec 31, 2020242.00K--
Dec 31, 2019---
Dec 31, 2018---
Sep 30, 2018---
Sep 30, 2017---
Sep 30, 2016---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Arvinas316.70M
Puma Biotechnology231.24M
REGENXBIO174.48M
Ginkgo Bioworks Holdings132.42M
Assembly Biosciences74.85M
Prelude Therapeutics22.42M
Capricor Therapeutics11.13M
Ovid Therapeutics1.58M
Revenue Rankings

AUTL News

More News